Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Evaluation of Maternal Safety Following Prenatal Cell and Gene Therapy for Hemophilia a in a Large Animal Model Demonstrates Absence of Maternal Exposure to the Cells or Gene Products Infused into the Fetus

Quan DM Pham, Martin Rodriguez, BSc, Ritu M Ramamurthy, Sunil George, PhD, Jorge Figueroa, MD, Anthony Atala, MD, Christopher B Doering, PhD, H. Trent Spencer, PhD, Christopher D Porada, PhD, M. Graca Almeida-Porada, MD PhD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-140883

Published: 2020

Journal Articles

Administration of Cells Engineered to Secrete Fviii-mcoET3 in Prenatal Sheep Recipients Results in Sustained Curative Fviii Plasma Levels for 3 Years after Birth, without Immune or Toxicity-Related Adverse Events

Martin Rodriguez, BSc, Brady Trevisan, Sunil George, PhD, Ritu M Ramamurthy, Andrew Rabah, Jordan E Shields, MS, Denise Schwahn, DVM, Jorge Figueroa, MD, Diane Meares, John Owen, MDMBA,FRCPC, Michael Gautreaux, PhD, D.ABHI, Anthony Atala, MD, Christopher B Doering, PhD, H. Trent Spencer, PhD, Christopher D Porada, PhD, M. Graca Almeida-Porada, MD PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-140845

Published: 2020

Journal Articles

Delivery of Fviii-mcoET3 to Previously Untreated Sheep Using Human Placental Cells Enables Durable Elevation of Plasma FVIII Levels and Avoids Inhibitor Formation

Brady Trevisan, Martin Rodriguez, BSc, Sunil George, PhD, Shannon Lankford, Jordan E Shields, MS, Jorge Figueroa, MD, Diane Meares, John Owen, MDMBA,FRCPC, Anthony Atala, MD, Christopher B Doering, PhD, H. Trent Spencer, PhD, Christopher D Porada, PhD, M. Graca Almeida-Porada, MD PhD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-140745

Published: 2020

Journal Articles

Recreating the Hematopoietic Microenvironment in Vitro Using Microfluidic “on-a-Chip” Technology Enables the Study of Interactions of Normal and Malignant HSPC with Specific Bone Marrow Niches

Sunil George, PhD, Julio Aleman, MS, M. Graca Almeida-Porada, MD PhD, Aleksander Skardal, PhD, Christopher D Porada, PhD

Blood (2017) 130 (Supplement 1): 3779.

https://doi.org/10.1182/blood.V130.Suppl_1.3779.3779

Published: 2017

Journal Articles

Prenatal Transplantation of Placental Cells Engineered to Express FVIII Leads to Corrective Plasma Levels of FVIII after Birth

M. Graca Almeida-Porada, MD PhD, Sunil George, PhD, Alshaima Morsi, MD, Nadia El-Akabawy, MD, Jorge Figueroa, Jordan E Shields, MS, Diane Meares, Andrew M. Farland, MD, Anthony Atala, MD, Christopher B Doering, PhD, H. Trent Spencer, PhD, Christopher D Porada, PhD

Blood (2017) 130 (Supplement 1): 361.

https://doi.org/10.1182/blood.V130.Suppl_1.361.361

Published: 2017

NARROW

Evaluation of Maternal Safety Following Prenatal Cell and Gene Therapy for Hemophilia a in a Large Animal Model Demonstrates Absence of Maternal Exposure to the Cells or Gene Products Infused into the Fetus

Administration of Cells Engineered to Secrete Fviii-mcoET3 in Prenatal Sheep Recipients Results in Sustained Curative Fviii Plasma Levels for 3 Years after Birth, without Immune or Toxicity-Related Adverse Events

Delivery of Fviii-mcoET3 to Previously Untreated Sheep Using Human Placental Cells Enables Durable Elevation of Plasma FVIII Levels and Avoids Inhibitor Formation

Recreating the Hematopoietic Microenvironment in Vitro Using Microfluidic “on-a-Chip” Technology Enables the Study of Interactions of Normal and Malignant HSPC with Specific Bone Marrow Niches

Prenatal Transplantation of Placental Cells Engineered to Express FVIII Leads to Corrective Plasma Levels of FVIII after Birth

Email alerts

ASH Publications

American Society of Hematology

Evaluation of Maternal Safety Following Prenatal Cell and Gene Therapy for Hemophilia a in a Large Animal Model Demonstrates Absence of Maternal Exposure to the Cells or Gene Products Infused into the Fetus

Administration of Cells Engineered to Secrete Fviii-mcoET3 in Prenatal Sheep Recipients Results in Sustained Curative Fviii Plasma Levels for 3 Years after Birth, without Immune or Toxicity-Related Adverse Events

Delivery of Fviii-mcoET3 to Previously Untreated Sheep Using Human Placental Cells Enables Durable Elevation of Plasma FVIII Levels and Avoids Inhibitor Formation

Recreating the Hematopoietic Microenvironment in Vitro Using Microfluidic “on-a-Chip” Technology Enables the Study of Interactions of Normal and Malignant HSPC with Specific Bone Marrow Niches

Prenatal Transplantation of Placental Cells Engineered to Express FVIII Leads to Corrective Plasma Levels of FVIII after Birth

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only